

Jacob E Berchuck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6035835/publications.pdf>

Version: 2024-02-01

28
papers

891
citations

567281

15
h-index

580821

25
g-index

30
all docs

30
docs citations

30
times ranked

1467
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 1 | Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190. | 6.4 | 40 |
| 2 | Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 928-938. | 7.0 | 29 |
| 3 | Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558. | 1.6 | 0 |
| 4 | Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS588-TPS588. | 1.6 | 3 |
| 5 | Genetic testing in prostate cancer management: Considerations informing primary care. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 360-371. | 329.8 | 15 |
| 6 | HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. <i>Nature Genetics</i> , 2022, 54, 670-683. | 21.4 | 39 |
| 7 | The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response. <i>Cancer Research</i> , 2022, 82, 2848-2859. | 0.9 | 17 |
| 8 | Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808. | 12.8 | 84 |
| 9 | Clinical considerations for the management of androgen indifferent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 623-637. | 3.9 | 30 |
| 10 | Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 1979. | 12.8 | 70 |
| 11 | Differential responses to taxanes and PARP inhibitors (PARPi) in <i>ATM</i> versus <i>BRCA2</i> -mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5040-5040. | 1.6 | 0 |
| 12 | Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. <i>Journal of Urology</i> , 2021, 205, 1689-1697. | 0.4 | 29 |
| 13 | Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220. | 3.0 | 17 |
| 14 | A Community Partnership to House and Care for Complex Patients. <i>NEJM Catalyst</i> , 2021, 2, . | 0.7 | 5 |
| 15 | Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. <i>European Urology</i> , 2021, 80, 295-303. | 1.9 | 15 |
| 16 | Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103463. | 4.4 | 3 |
| 17 | Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 709-718. | 2.4 | 44 |
| 18 | Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1041-1043. | 30.7 | 161 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1055. | 7.1 | 26 |
| 20 | Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 1366-1373. | 2.4 | 40 |
| 21 | Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084. | 3.4 | 47 |
| 22 | Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-43. | 1.6 | 3 |
| 23 | Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 728-728. | 1.6 | 2 |
| 24 | Detection of urothelial carcinoma using plasma cell-free methylated DNA.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5046-5046. | 1.6 | 0 |
| 25 | Did you “miss” me? A subtle case of intravascular large B-cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 162-163. | 4.1 | 0 |
| 26 | An Often-Overlooked Etiology of Pleuritic Chest Pain. <i>Journal of General Internal Medicine</i> , 2016, 31, 138-138. | 2.6 | 2 |
| 27 | A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 430-434. | 0.8 | 23 |
| 28 | Proteomic and Genetic Approaches Identify Syk as an AML Target. <i>Cancer Cell</i> , 2009, 16, 281-294. | 16.8 | 140 |